anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A double-blind, randomized, multicenter, multinational study evaluated and compared the efficacy and safety of three different regimens for emergency contraception. Subjects were enrolled at 15 sites in 10 countries; the racial/ethnic characteristics of the study population overall were 54% Chinese, 34% Caucasian, and 12% Black or Asian (other than Chinese). 2,381 healthy women with a mean age of 27 years, who needed emergency contraception within 72 hours of unprotected intercourse were involved and randomly allocated into one of the two levonorgestrel groups. A single dose of 1.5 mg of levonorgestrel (Plan B One-Step) was administered to women allocated into group 1. Two doses of 0.75 mg levonorgestrel 12 hours apart (Plan B) were administered to women in group 2. In the Plan B One-Step group, 16 pregnancies occurred in 1,198 women and in the Plan B group, 20 pregnancies occurred in 1,183 women. The number of pregnancies expected in each group was calculated based on the timing of intercourse with regard to each woman’s menstrual cycle. Among women receiving Plan B One-Step, 84% of expected pregnancies were prevented and among those women taking Plan B, 79% of expected pregnancies were prevented. The expected pregnancy rate of 8% (with no contraceptive use) was reduced to approximately 1% with Plan B One-Step.

Emergency contraceptives are not as effective as routine contraception since their failure rate, while low based on a single use, would accumulate over time with repeated use [see INDICATIONS AND USAGE (1)].

In the clinical study, bleeding disturbances were the most common adverse event reported after taking the levonorgestrel-containing regimens. More than half of the women had menses within two days of the expected time; however, 31% of women experienced change in their bleeding pattern during the study period; 4.5% of women had menses more than 7 days after the expected time.
Participants in the stage I were randomized to 6 BTP episodes, in which 2 BTP episodes were treated with placebo (0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
There has been an increase in lifestyle related diseases worldwide. Living a healthy lifestyle is important to prevent lifestyle-related diseases such as heart disease, obesity, diabetes, mental health issues, certain cancers, autoimmunity and gastro-intestinal disease. The economic impact of these lifestyle-related diseases in Europe alone is set to exceed €200 billion by 2030. Worldwide, one in five people are at an increased risk of developing severe COVID-19, mostly as a result of underlying lifestyle-related diseases. Additionally, global efforts to manage COVID-19 infection have disrupted regular care required by those with these issues. Dealing with this requires that people better manage their own health and address lifestyle related factors that increase the risk associated with such diseases, including inactivity, substance abuse and unhealthy diet. These risk factors are modifiable and can be reduced by health interventions and tools to support a healthy lifestyle.

The COVID-19 pandemic caused prolonged feelings of fear, uncertainty and isolation among the general population. This is likely to impact vulnerable members of society, such as young people, elderly people and those in ethnic minority communities in greater proportions. Children and adolescents are experiencing increased adverse mental health effects such as social isolation, loneliness, depression and anxiety, during the Covid-19 pandemic. Irish adults aged 70 and over have reported worse mental health and increased feelings of loneliness due to cocooning throughout the pandemic. This social isolation and loneliness puts them at increased risk of cognitive and cardiovascular decline. It is important that we prioritise the development of strategies to maintain social engagement, manage loneliness and encourage continued physical activity among older people.

Work habits are currently changing at a rapid pace. Significant sections of our workforces are now working from home and at least 50% are expected to remain at home, even after the current pandemic has resolved. Reports indicate that a significant proportion of this workforce is experiencing issues with disconnection and mental health. As a result, understanding the impact of remote and flexible working arrangements on employee health and mental wellbeing has been included as a research priority within psychological science. While there is evidence that remote working has positive effects on well-being, these effects are not consistent. Remote working may also lead to greater levels of professional isolation, reduced work-life balance, increase work-related fatigue and have negative impacts on well-being. This study is being conducted to better understand citizen's needs in relation to living a healthier lifestyle.
The present invention relates to a traditional Chinese medicine preparation for the treatment of rosacea, which takes more than 10 Chinese herbal medicines of radix rehmanniae glutinosae, danshen root, figwort root, white mulberry root-bark etc. as the raw materials. The present invention has the effects of clearing heat-toxin, cooling blood and promoting blood circulation. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine preparation for the treatment of rosacea. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
A pharmaceutical formulation of cannabis compounds is provided herein, which is suitable for pulmonary delivery. The formulation comprises a volatile liquid, which includes a mixture of: a cannabis oil extract having a known amount of a medicinal cannabis compound, and an aerosol precursor. The medicinal cannabis compound may include cannabinoids, terpenes, flavonoids, phytosterols, and/or other medicinally relevant compounds found in cannabis. Also provided is an apparatus for converting the volatile liquid into particles suitable for pulmonary delivery. The apparatus includes a reservoir holding the volatile liquid, and an atomizer adapted to atomize the volatile liquid. Activation of the atomizer causes at least a portion of the volatile liquid to atomize to form inhalable particles containing medicinal cannabis compounds. Using the electronic apparatus, the medicinal cannabis compounds may be administered to a patient in a controlled unit dose.
PURPOSE: A composition containing Empetrum nigrum var. japonicum extract for radiation protection is provided to suppress ROS(reactive oxygen species) generation and recover antioxidative elements. CONSTITUTION: A composition for radiation protection contains Empetrum nigrum var. japonicum extract as an active ingredient. The Empetrum nigrum var. japonicum extract is prepared using water or organic solvent. The radiation is gamma-irradiation. The radiation protection is caused by promoting antioxidative activity of tissues or cells in the body. The radiation protection includes suppression of intracellular DNA damage, lipid peroxidation, or protein deformation.
Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
The present invention relates to a contraception medicament and pharmacy field. The compound contraceptive medicament is prepared to a biological degradation type long-effect microsphere preparation for injection. The invention settles the problems of large side effect, inferior compliance property and liver-kidney function effect of prior oral contraceptive medicament, and complicated using method, large side effect, etc. of traditional unilateral abiotic degradation type long-effect contraception implantation agent. The invention provides a long-term compound contraception microsphere injection which has the advantages of good contraception effect, small side effect and easy use, and a preparing method thereof. The microsphere comprises gestodene, estrogen and biological degradation polymer. The detailed content is in the instruction book. The product of the invention can stably and synchronously release two effective components in a long time. The inside and outside relativity of effective component is excellent.
High positive end-expiratory pressure (PEEP) level and prone positioning (PP) are recommended in patients with moderate to severe acute respiratory distress syndrome (ARDS) in order to recruit lung and thus to improve oxygenation. Thus, high PEEP level and prone positioning will be more effective in patients with high potential for lung recruitment. Recently, the Recruitment-to-Inflation Ratio (R/I ratio) has been described and validated in patients with ARDS to estimate the potential for lung recruitment. In this regard, the R/I ration may be of interest to titrate PEEP level in patients with ARDS. This would be of particular interest in COVID-19 patients with ARDS, since different ARDS phenotypes with heterogeneous potential of lung recruitment have been described in these patients. However, the effects of prone positioning on R/I ratio have been scarcely described so far. Thus, the main goal of this study is to investigate the effects of prone positioning on the R/I ratio in COVID-19 patients with ARDS. The second goal of this study is to determine the effects of prone positioning on oxygenation and respiratory mechanics according to the R/I ratio.
This is a multicenter, randomized, controlled clinical study comparing two different progestogens for pituitary suppression in normo-responding patients undergoing controlled ovarian hyperstimulation (COH) for egg donation. Patients will be recruited on the day they begin the egg donation program. Before inclusion, patients must meet all inclusion and exclusion criteria and provide written informed consent. Each patient will be assigned a patient code based on the treatment group they are included in. Treatment with the assigned progestogens will start on the first day of COH. The standard protocol for egg donation will be followed, including stimulation with FSHr (Puregon®), pituitary suppression with either Medroxyprogesterone acetate (Progevera®) or Desogestrel (Cerazet®), and trigger with GnRH agonist (Triptorelin acetate, Decapeptyl®) 36 hours before oocyte retrieval. Patients will continue taking the assigned progestogen throughout the COH period. Oocyte quality will be assessed based on maturity and morphology, with mature oocytes classified as normal or good quality and abnormal oocytes categorized into intracytoplasmic and extracytoplasmic abnormalities. Quality assessment will be performed by two blinded embryologists.
A composition for promoting repair of damaged tissue, being a cross-linked alginate solution, which can be maintained in liquid form indefinitely (under constant conditions) and only gels in vivo. This cross-linked alginate solution is an ideal material to be used for tissue repair. Injection of said material into cardiac tissue post-myocardial infarct induced tissue regeneration. The invention provides such injectable solution, as well as compositions and methods of preparation thereof. The invention also provides various methods and uses of the cross-linked alginate solution, for cardiac tissue regeneration, induction of neo-vascularization, enhancing SDF-1 expression and guiding stem cell chemotaxis, among others. A kit for tissue repair is also provided.
For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
PURPOSE: To obtain the stable, small and single preparation containing two or more kinds of medicinal active ingredients which are liable to change, when compounded with each other. CONSTITUTION: A core containing isopropylantipyrine and a medicinal active ingredient causing a change, when compounded with the isopropylantipyrine, is produced. The core is preferably a tablet, and on the production of the core, if necessary, medicinally usable additives are suitably compounded. The core is successively covered with plural coating layers by known coating methods and by the use of known devices. The first coating layer comprises a barrier layer containing hydroxypropylmethyl cellulose, etc., as a skin agent. The amount of the coating film is 1-10wt.% based on the core. The second layer is produced by coating a solution containing the isopropylantipyrine. The third layer comprises a moisture-proof layer containing a water-insoluble polymer and a water-soluble polymer. The composition comprising polyvinylacetal dimethylaminoacetate (3-25wt.%) and hydroxypropylmethyl cellulose (75-97wt.%) is especially preferably coated for the third layer.
The invention belongs to the field of organizational project and medical materials and relates to an endothelial cell bioreactor as well as a preparation method and an application thereof. A polyfluortetraethylene non-woven fabric is used as a carrier for the growth of endothelial cells, and the polyfluortetraethylene non-woven fabric and a hollow fiber bioreactor constitute the bioreactor. The non-woven fabric is positioned in a clearance outside the hollow fiber so as to form a reactor which takes the polyfluortetraethylene non-woven fabric as the carrier. The endothelial cells are grown on the non-woven fabric so as to form the endothelial cell bioreactor. The number of the endothelial cells in the bioreactor is more than 3*10<9>. The endothelial cell bioreactor can improve hemodynamical indexes of organisms suffering sepsis and the disorder state of inflammation and hemoglutination, prolong the life time and improve the prognosis. The endothelial cell bioreactor can be used for curing severe sepsis.
INTRODUCTION: Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), characterized by its monoclonal lymphoproliferative nature, is an indolent but incurable malignancy. The treatment landscape of CLL/SLL has drastically transformed in the last decade since the introduction of targeted therapy and immune-effector T-cell therapy. The paradigm shift from chemoimmunotherapy to targeted and cellular therapies was largely driven by improved efficacy and safety. With the success of targeted therapies, novel agents and combinations are rapidly emerging on the horizon.
AREAS COVERED: In this review, we will summarize clinical evidence supporting current and emerging therapies with emphasis on investigational therapies and novel combinations of commercial agents. Clinical trials were identified via clinicaltrials.gov, and a PubMed literature search was last performed in June 2024.
EXPERT OPINION: With the availability of more effective and better-tolerated treatments for CLL/SLL, the role of early intervention should be further investigated due to its potential to alter disease course, delay progression, and improve overall survival rates. With many highly effective agents and combinations expected to become commercially available, attention to safety profiles and careful selection of patients for each treatment will be critical, with consideration of comorbidities, logistical issues, and financial burden of treatment.
Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
<b>Background and Objective:</b> The sustainable management and conservation of fish biodiversity depends on studying fish biology. In this study, the length-weight relationships and condition factors of <i>Tilapia sparrmanii</i> were observed to gain a better understanding of their ecological and nutritional conditions. This information is crucial for the effective management of fisheries. <b>Materials and Methods:</b> During the study, 100 <i>T. sparrmanii</i> were collected from the Molepo Dam from October, 2022 to March, 2023. This fish's condition factor (CF) and length-weight relationship (LWR) were studied. To determine the size of each fish, the total length was measured using a caliper with a precision of 0.1 mm and the weight using a balance with an accuracy of 0.1 g. Differences were analyzed using ANOVA with the Tukey's <i>post hoc</i> test. A non-parametric Chi-square test was employed to evaluate the differences in sexes each month. <b>Results:</b> Their total length and body weight ranged from 4-15 cm and 0.96-57.96 g, respectively. The study found a strong positive relationship between the length and weight of the fish (r = 0.96). The regression coefficient (b) was more than 3.0, indicating a positive allometric growing rate. The condition factors (K) of males and females were not significantly different (p>0.05). The lowest CF value was observed in March (K = 1.01±0.03) and the highest in December (K = 1.73±0.12). The sex ratio of 1.0 male to 1.15 female was observed, which was significantly different from the theoretical ratio of one male to one female. This suggests that males were not significantly more than females (p>0.05). <b>Conclusion:</b> The study found that <i>T. sparrmanii</i> in Molepo Dam exhibited allometric growth, as evidenced by a strong correlation between length and weight represented by a high "r" value. This fish is in good condition because it has no competition for food due to ecological factors.
Participants randomized to the time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours. During the eating window there will be no restrictions on types or quantities of foods consumed. Moreover, participants will not be required to monitor calorie intake during the ad libitum eating period. During the fasting period, participants will be encouraged to drink plenty of water and will be allowed to consume calorie-free beverages.
The invention relates to a liquid solution of tadalafil which is bioequivalent to the original Cialis tablet, in a liquid, soluble and mucoadhesive form, packaged in a spray bottle for oral and sublingual use. Tadalafil obtained in this way is used by spraying into the oral and sublingual regions, the amount sprayed being adjustable by the patient to the desired dose, 2.5 mg of tadalafil being released with each spray. The dose can be adjusted between 2.5 and 20 mg (which are the Cialis doses, i.e. 2.5, 5, 10 and 20 mg) at the request of the doctor or the wish of the patient, depending on age and the degree and type of problem to be treated. The solubilisation reached, which is more than 20,000 times the original solubilisation of Cialis, with gradual absorption without modifying the bioavailability of the reference tablet (Cialis), allows treatment of prostatic hyperplasia, erectile dysfunction or pulmonary hypertension etc., in an unprecedented manner in relation to the pharmaceutical forms already known. The formulation can be produced without the active substance tadalafil at first, in order to receive the tadalafil mixture as a liquid solution in a separate step, maintaining the same principles of bioequivalence to Cialis, with solubility, mucoadhesion and the mode of application.
The UK-PATHways program preliminary successes during the first three years are clear: enrolled mothers (n\>200) have reduced relapse, increased treatment compliance, and improved neonatal outcomes when compared to non-enrolled OUD mothers. However, at this time, UK-PATHways is only available at the main healthcare campus in Lexington, KY. Many eligible patients reside great distances from our clinical home and some current patients travel hours to access this valuable resource. While Medication Assisted Therapy (MAT) has become increasingly available in our region, many of the components of the UK-PATHways program are not readily accessible in rural Central and Eastern Kentucky and the quality of programming with MAT treatment is not standardized in these locations. Furthermore, rural patients continue to face challenges related to stigma of their OUD and transportation difficulties if they desire more comprehensive services. The proposed study will evaluate the introduction of essential components of the UK-PATHways program into rural communities and identify the optimal intervention strategies for expansion of services and to improve the treatment of OUD for rural patients. Specific aims include the following: Aim 1) Conduct a randomized cluster trial using a 'hub and spoke' study design, comparing two delivery modes (local GROUP care vs TELEMEDICINE) for the delivery of a UK-PATHways based patient education curriculum at participating rural regional sites. Each regional site will be randomized to support one of two study arms: 1) Prenatal group care led by a perinatal nurse facilitator or substance use counselor with a peer support specialist (GROUP arm); or, 2) Telemedicine consultation with substance use counselor or perinatal nurse facilitator based at the 'hub' site (TELEMEDICINE arm); and Aim 2) Evaluate the relative effectiveness of each study arm on primary and secondary maternal and neonatal outcomes as compared to the established UK-PATHways program (UK PATHways: Hub) at the University of Kentucky.
Participants assigned to the UC group will proceed through the weight management program provided by the center. The login credential for UC participants will provide access to a secure website to complete data collection (i.e., a survey battery, physical activity monitoring) at W1, W2, and W3.